Abstracts
Plasma and Platelet Lipid Composition
Pantethine can affect plasma and platelet lipid composition
In a single-blind, crossover, completely randomized study, the effects of oral treatment with pantethine or placebo on fatty acid composition of plasma and platelet phospholipids were investigated in 10 hyperlipoproteinemic patients. A significant decrease of total cholesterol and total phospholipids was observed both in plasma and in platelets after a twenty-eight-day treatment. In plasma, pantethine induced a decrease of the ratio sphingomyelin/phosphatidylcholine. Moreover, a relative increase of n3-polyunsaturated fatty acids both in plasma and in platelet phospholipids and a decrease of arachidonic acid in plasma phospholipids were observed. These results indicate that pantethine can affect plasma and platelet lipid composition with possibly favorable influences on the determinants of cell membrane fluidity.
Prisco D Rogasi PG Matucci M Paniccia R Abbate R Gensini GF Neri Serneri GG Effect of oral treatment with pantethine on platelet and plasma phospholipids in IIa hyperlipoproteinemia.; Angiology (1987 Mar) 38(3):241-7
Hyperlipoproteinemia
Possible role of pantethine in the treatment of hyperlipoproteinemia
Following a brief outline of current knowledge concerning atherosclerosis and its treatment, the authors describe the results obtained by treating with pantethine (900-1200 mg daily for 3 to 6 months) a series of 7 children and 65 adults suffering from hypercholesterolemia alone or associated with hypertriglyceridemia (types IIa and IIb of Fredrickson's classification). Pantethine treatment produced significant reduction of the better known risk factors (total cholesterol, LDL-cholesterol, triglycerides, and apo-B) and a significant increase of HDL-cholesterol (signally HDL2) and apolipoprotein A-I. The authors conclude with a discussion of these results and of the possible role of pantethine in the treatment of hyperlipoproteinemia, in view of its perfect tolerability and demonstrated therapeutic effectiveness.
Bertolini S Donati C Elicio N Daga A Cuzzolaro S Marcenaro A Saturnino M Balestreri R. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children., Int J Clin Pharmacol Ther Toxicol (1986 Nov) 24(11):630-7
Exercise & Pantethine Supplements
Exercise
According to this study, pantethine and allithium do not improve exercise performance or metabolism. This study involved the effect of allithiamin and pantethine on physiological and performance responses. During this study, six trained cyclists ingested either a placebo or a combination of allithiamin and pantethine/pantothenic acid compound (AP). None of the agents indicated any significant changes.
Webster MJ: Physiological and performance responses to supplementation with thiamin and pantothenic acid derivatives, Eur J Appl Physiol 1998 May; 77(6): 486-91
Diabetes & Lipid Abnormalities
Diabetes & Lipid Abnormalities
After a review of the clinical studies on the treatment of diabetic patients with pantethine, the authors discuss the results obtained in a postmarketing surveillance (PMS) study on 1045 hyperlipidemic patients receiving pantethine (900 mg/day on average). Of these patients, 57 were insulin-dependent (Type I) and 241 were non insulin-dependent (Type II) diabetics. Beyond the epidemiological considerations made possible by a PMS study, the authors show that pantethine brought about a statistically significant and comparable improvement of lipid metabolism in the three groups of patients, with very good tolerability. Pantethine should therefore be considered for the treatment of lipid abnormalities also in patients at risk such as those with "diabetes" mellitus.
Donati C Bertieri RS Barbi G , Pantethine, diabetes mellitus and "atherosclerosis". Clinical study of 1045 patients, Clin Ter (1989 Mar 31) 128(6):411-22 (Italian)
| Signup Free Applied Health Journal |
||||
|
FREE Sample Issue Your email address is all we need to start you on a better path to health. We respect your privacy.
|
